Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Medicinal Research Reviews Année : 2021

Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness

Tania Gamberi
  • Fonction : Auteur
Tania Fiaschi
  • Fonction : Auteur
Alessandra Modesti
  • Fonction : Auteur
Flavia Sorbi
  • Fonction : Auteur
Francesca Magherini
  • Fonction : Auteur
  • PersonId : 1139564

Résumé

Auranofin is an oral gold(I) compound, initially developed for the treatment of rheumatoid arthritis. Currently, Auranofin is under investigation for oncological application within a drug repurposing plan due to the relevant antineoplastic activity observed both in vitro and in vivo tumor models. In this review, we analysed studies in which Auranofin was used as a single drug or in combination with other molecules to enhance their anticancer activity or to overcome chemoresistance. The analysis of different targets/pathways affected by this drug in different cancer types has allowed us to highlight several Med Res Rev.
Fichier principal
Vignette du fichier
med.21872.pdf (1.85 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03461453 , version 1 (01-12-2021)

Identifiants

Citer

Tania Gamberi, Giovanni Chiappetta, Tania Fiaschi, Alessandra Modesti, Flavia Sorbi, et al.. Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness. Medicinal Research Reviews, 2021, ⟨10.1002/med.21872⟩. ⟨hal-03461453⟩
33 Consultations
85 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More